Teva launches topotecan injection

NORTH WALES, Pa. — Teva Health Systems has launched a generic injectable drug for small-cell lung cancer, the company said Tuesday.

Teva, a subsidiary of Teva Pharmaceuticals, itself a subsidiary of Israel-based Teva Pharmaceutical Industries, announced the launch of topotecan injection in the 1 mg-per-1 mL strength, in 4 mL, single-dose vials.

The drug is a generic version of GlaxoSmithKline's Hycamtin.


Are you a pharmacy technician working in the retail industry? Find our group on Facebook for more stories like this and join the conversation.